Recent News

• 11.03.2025 - Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
• 10.30.2025 - Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
• 10.25.2025 - Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
• 10.23.2025 - Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
• 10.20.2025 - Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
• 10.06.2025 - Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
• 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.03.2025 - Cantor Global Healthcare Conference 2025
• 08.25.2025 - Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Recent Filings

• 10.30.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.30.2025 - EX-99.1 EX-99.1
• 10.30.2025 - 8-K Current report
• 10.27.2025 - 8-K Current report
• 10.08.2025 - 4/A Statement of changes in beneficial ownership of securities
• 10.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.07.2025 - 3 Initial statement of beneficial ownership of securities
• 10.06.2025 - 8-K Current report
• 09.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.09.2025 - 4 Statement of changes in beneficial ownership of securities